NCPDP Annual Conference: Track Sessions

May 3, 2022

9:15 am – 10:15 am
Ken Kleinberg, FHIMSS, MA
Practice Lead, Innovative Technologies
Point-of-Care Partners
Andrew Mellin, MD, MBA
Vice President, Chief Medical Information Officer
Surescripts
10:30 am – 11:30 am
Megan Marchal
Clinical Pharmacist
CoverMyMeds
Josh Howland
Senior Vice President, Strategy and Development
PioneerRX
Billy Chow
Chief Pharmacy Officer
STChealth
1:45 pm – 2:15 pm
Matt McGrath
Vice President, Pharmacy Solutions
Experian Health
Lisa Schwartz, PharmD, RPh
Senior Director, Professional Affairs
National Community Pharmacists Association
2:30 pm – 3:00 pm
Joseph Kenkel
Manager, Logistics Business Development
ScriptDrop
2:30 pm – 3:00 pm
Kathleen Dynan Black, BS, MBA
Director, Government Strategy
Pfizer

May 4, 2022

Anurati Mathur
Chief Executive Officer
Sempre Health

2:30 pm – 3:00 pm
Elliott Garber, DVM
Vice President, Growth
Instinct Science

Ben Shirley, CPHQ
Director, Performance Measurement
Pharmacy Quality Alliance (PQA)

Meghan O’Connor
Partner
Quarles & Brady LLP

Suzanne Broderick, Esq.

The Phoenix Law Group, PLC

 

340B Drug Pricing Program

  • Tuesday, May 3, 2022
  • 2:30 pm – 3:00 pm

The 340B Drug Pricing Program facilitates access to mandatory discounts on “covered outpatient drugs” for certain statutorily specified categories of healthcare providers, referred to as “covered entities.” As a condition of eligibility in the 340B Program, covered entities must not run afoul of two core program requirements: the prohibition against “diversion” (i.e., transferring a 340B drug to an individual who is not a “patient” of the covered entity) and “duplicate discounts” (i.e., obtaining a Medicaid drug rebate on a unit of product purchased through the 340B Program). Currently, there is limited guidance from the two relevant federal agencies — the Health Resources and Services Administration (HRSA) and the Centers for Medicare and Medicaid Services (CMS) — with respect to how full compliance with these prohibitions should be operationalized. As a result, any existing operational standards for 340B compliance are not universally used. Potential solutions will be discussed.

Track Session Speakers

  • Kathleen Dynan Black, BS, MBA
  • Director, Government Strategy
  • Pfizer
NCPDP-Elite Partner

Covermymeds logo             FDB

NCPDP’s Elite Partner Program establishes the highest level of sustained support for the valuable work of NCPDP in advancing patient safety and interoperability.

Need More Info?

We would love to hear from you. Send us a message with your comment or question and a member of our staff will contact you shortly.

       
Stay Connected